The information provided in this web site is intended to educate the reader about certain medical conditions and certain possible treatments. It is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. If you believe you, suffer from the conditions described herein, please see your health care provider. Do not attempt to treat yourself or anyone else without proper medical supervision.
Read the Full Disclaimer
Page 1 of 1
Actelion obtains option to acquire privately-held Trophos Late-stage Phase III compound in Amyotrophic Lateral Sclerosis to report data in late 2011 – Novel therapeutic approach to be furth
Trophos completes patient enrolment in pivotal phase 3 efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) Topline results of the study are expected 4th quarter 20
Marseille, France, March 8, 2010 - Trophos, the pharmaceutical company specialising in therapies for orphan diseases including ALS, announces today, on behalf of the MitoTarget consortium, the lau
Trophos initiates pivotal efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) Physicians and patients will be able to follow progress through dedicated EU MitoTa
EUR 7 million grants boost Trophos cholesterol-oxime programs for ALS, MS and other neurodegenerative diseases EU awards EUR 6 million (USD 8 million) to Trophos led consortium France’s AN
The MitoTarget project is supported by the European Union under the 7th Framework Programme for RTD - Project MitoTarget - Grant Agreement HEALTH-F2-2008-223388
